课题基金 / 基金详情

项目摘要

项目成果

Sewon Kang的其他基金

相似基金

相关文献

中文摘要
翻译
皮肤中过多的胶原沉积是硬皮病的标志。目前没有安全与/或
英文摘要
Excessive collagen deposition in the skin is a hallmark of scleroderma. Currently there are no safe and/or effective therapies. Excessive accumulation of collagen is responsible for the markedly thickened and hard feel to the involved skin of scleroderma. Therefore, a therapy that can safely enhance collagen breakdown is expected to improve it. We have accumulated solid evidence that UV irradiation of human skin activates a complex signaling cascade in cells that ultimately results in a several fold increase in the amount of matrix metalloproteinases (MMPs) with consequent degradation of collagen, while simultaneously inhibiting new procollagen synthesis. Thus, by removing already present dermal collagen and suppressing production of new collagen, UV is capable of causing a net collagen loss in human skin. As a phototherapeutic device however, both UVB (290-320nm) and UVA1 (340-400nm) have significant limitations. More energetic UVB is associated with sunburn reaction, and its carcinogenic potential is well established. UVA1 is safer and better tolerated by human skin. However, we have learned that both natural and UV-induced skin pigmentation are effective blockers of UVA1. Scleroderma affects subjects with all levels of skin pigmentation (types I-VI). An antifibrotic treatment modality that is not influenced by skin color will offer a significant medical advancement, especially in darkly pigmented African American, Hispanic, Indian, or Asian patients (types V&VI). Our preliminary data indicate that infrared irradiation (IR; specifically 700-4,000nm) that raises skin surface temperature to 41 degrees C is capable of safely inducing MMPs and inhibiting procollagen irrespective of human skin pigmentation. Thus we hypothesize that IR will also improve scleroderma and other fibrotic diseases. We propose to 1) fully characterize the ability of IR to reduce collagen in normal skin, and 2) obtain preliminary data of the IR effect on scleroderma skin. The data generated with the assistance of RDCC will form the basis for an application to the NIH to fund a multicenter IR therapeutic trial in scleroderma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OPEN LABEL STUDY OF TETRATHIOMOLYBDATE IN TREATMENT OF PSORIASIS VULGARIS
University of Michigan Multidisciplinary Clinical Research (RMI)
Univ of Michigan Multidisciplinary Clinical Resea**(RMI)
University of Michigan Multidisciplinary Clinical Research (RMI)
海外基金